{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:21:42Z","timestamp":1783621302967,"version":"3.55.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cll.2026.02.006","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:20:43Z","timestamp":1774869643000},"page":"295-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updates in Antiphospholipid Syndrome Laboratory Diagnosis"],"prefix":"10.1016","volume":"46","author":[{"given":"Geoffrey D.","family":"Wool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemostasis"},{"issue":"5","key":"10.1016\/j.cll.2026.02.006_bib2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.14740\/jocmr4154","article-title":"The issue of the antiphospholipid antibody syndrome","volume":"12","author":"Oliveira","year":"2020","journal-title":"J Clin Med Res"},{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtha.2024.10.022","article-title":"An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC subcommittee on lupus anticoagulant\/antiphospholipid antibodies","volume":"23","author":"Devreese","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.cll.2026.02.006_bib4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2014-02-554980","article-title":"Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS","volume":"124","author":"Proulle","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cll.2026.02.006_bib5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.40901","article-title":"The epidemiology of antiphospholipid syndrome: a population-based study","volume":"71","author":"Duarte-Garc\u00eda","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"7","key":"10.1016\/j.cll.2026.02.006_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41584-018-0032-6","article-title":"Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?","volume":"14","author":"Meroni","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.cll.2026.02.006_bib7","series-title":"CLSI H60 laboratory testing for the lupus anticoagulant; approved guideline","author":"Ledford-Kramer","year":"2014"},{"issue":"8","key":"10.1016\/j.cll.2026.02.006_bib8","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3390\/jcm11082164","article-title":"Laboratory diagnosis of antiphospholipid syndrome: insights and hindrances","volume":"11","author":"Vandevelde","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.cll.2026.02.006_bib9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.cll.2026.02.006_bib10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1365-2141.2000.02069.x","article-title":"Guidelines on the investigation and management of the antiphospholipid syndrome","volume":"109","author":"Greaves","year":"2000","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.cll.2026.02.006_bib11","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1538-7836.2009.03555.x","article-title":"Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant\/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis","volume":"7","author":"Pengo","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.cll.2026.02.006_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2012.09037.x","article-title":"British committee for standards in haematology. Guidelines on the investigation and management of antiphospholipid syndrome","volume":"157","author":"Keeling","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.cll.2026.02.006_bib13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/jth.12537","article-title":"Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH","volume":"12","author":"Devreese","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.cll.2026.02.006_bib14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/jth.13976","article-title":"Subcommittee on lupus anticoagulant\/antiphospholipid antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH","volume":"16","author":"Devreese","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.cll.2026.02.006_bib15","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the scientific and standardization committee for lupus anticoagulant\/antiphospholipid antibodies of the international society on thrombosis and haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.16308","article-title":"Addendum to British society for haematology guidelines on investigation and management of antiphospholipid syndrome, 2012 (br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants","volume":"189","author":"Arachchillage","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.cll.2026.02.006_bib17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jth.14846","article-title":"Lupus anticoagulant detection in anticoagulated patients. Guidance from the scientific and standardization committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and haemostasis","volume":"18","author":"Tripodi","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.cll.2026.02.006_bib18","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"6","key":"10.1016\/j.cll.2026.02.006_bib19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1055\/s-0043-1776910","article-title":"Risk factors for antiphospholipid antibodies and antiphospholipid syndrome","volume":"50","author":"Aguirre Del-Pino","year":"2024","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"10.1016\/j.cll.2026.02.006_bib20","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1515\/cclm-2016-0014","article-title":"Distribution of antiphospholipid antibodies in a large population-based German cohort","volume":"54","author":"Manukyan","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"10.1016\/j.cll.2026.02.006_bib21","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/ijlh.13094","article-title":"Extended persistence of antiphospholipid antibodies beyond the 12-week time interval: association with baseline antiphospholipid antibodies titres","volume":"41","author":"Devignes","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"14","key":"10.1016\/j.cll.2026.02.006_bib22","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/0961203314545410","article-title":"Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study","volume":"23","author":"Mustonen","year":"2014","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.cll.2026.02.006_bib23","first-page":"e470","article-title":"Evaluation of frequency, clinical correlation, and antibodies confirmation profile in patients with suspected antiphospholipid syndrome","volume":"5","author":"Martins","year":"2021","journal-title":"TH Open Companion J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.cll.2026.02.006_bib24","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/bloodadvances.2021006011","article-title":"Lupus anticoagulant test persistence over time and its associations with future thrombotic events","volume":"6","author":"Colling","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.cll.2026.02.006_bib25","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/jth.14560","article-title":"Clinical and laboratory practice for lupus anticoagulant testing: an International Society of Thrombosis and Haemostasis Scientific and Standardization Committee survey","volume":"17","author":"Cohen","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.cll.2026.02.006_bib26","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood-2013-04-496257","article-title":"Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review","volume":"122","author":"Garcia","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cll.2026.02.006_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102385","article-title":"Testing for the lupus anticoagulant: the good, the bad, and the ugly","volume":"8","author":"Favaloro","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"12","key":"10.1016\/j.cll.2026.02.006_bib28","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1016\/j.jtha.2023.08.009","article-title":"Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay","volume":"21","author":"Moore","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.cll.2026.02.006_bib29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/rth2.12006","article-title":"Application of different lupus anticoagulant diagnostic algorithms to the same assay data leads to interpretive discrepancies in some samples","volume":"1","author":"Moore","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"10.1016\/j.cll.2026.02.006_bib30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ajcp\/aqae044","article-title":"The utility of the dilute prothrombin time in the interpretation of antiphospholipid syndrome testing","volume":"162","author":"Mehr","year":"2024","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"10.1016\/j.cll.2026.02.006_bib31","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/jth.15438","volume":"19","author":"Moore","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.cll.2026.02.006_bib32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-0033-1334865","article-title":"Comparison of six dilute russell viper venom time lupus anticoagulant screen\/confirm assay kits","volume":"39","author":"McGlasson","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/j.cll.2026.02.006_bib33","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/ajcp\/aqae004","article-title":"To normalize or not?: Dilute Russell viper venom time testing","volume":"161","author":"Zhang","year":"2024","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.cll.2026.02.006_bib34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ajcp\/aqae054","article-title":"Dilute Russell viper venom time interpretation: influence of lot changes and normalization","volume":"162","author":"Wool","year":"2024","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.cll.2026.02.006_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ijlh.13342","article-title":"Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory","volume":"43","author":"Siriez","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"8","key":"10.1016\/j.cll.2026.02.006_bib36","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/jth.14829","article-title":"Unveiling the complex effects of direct oral anticoagulants on dilute Russell\u2019s viper venom time assays","volume":"18","author":"Hillarp","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.cll.2026.02.006_bib37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-0042-1744363","article-title":"Testing for lupus anticoagulants","volume":"48","author":"Moore","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/j.cll.2026.02.006_bib38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ajcp\/aqx035","article-title":"The effects of Indirect- and direct-acting anticoagulants on Lupus anticoagulant assays","volume":"147","author":"Seheult","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cll.2026.02.006_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.715878","article-title":"Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the International Guidelines","volume":"8","author":"Pastori","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12676","article-title":"Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants","volume":"6","author":"Favaloro","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/ijlh.12138","article-title":"Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin","volume":"36","author":"Martinuzzo","year":"2014","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"10.1016\/j.cll.2026.02.006_bib42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/rth2.12264","article-title":"The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: can activated carbon eliminate false-positive results?","volume":"4","author":"De Kesel","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"10.1016\/j.cll.2026.02.006_bib43","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/jth.14894","article-title":"Direct oral anticoagulant adsorption: impact on lupus anticoagulant testing-Review of the literature and evaluation on spiked and patient samples","volume":"18","author":"De Kesel","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.cll.2026.02.006_bib44","doi-asserted-by":"crossref","first-page":"E166","DOI":"10.1002\/ajh.25465","article-title":"High frequency of false-positive results of aPTT-based lupus anticoagulant tests in patients receiving argatroban","volume":"94","author":"Villalba","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.cll.2026.02.006_bib45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2009.09.001","article-title":"Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results?","volume":"125","author":"Schouwers","year":"2010","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ijlh.14224","article-title":"False positive lupus anticoagulant tests in patients with high C-reactive protein: a comparison of two hexagonal phase reagents","volume":"46","author":"Mize","year":"2024","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"10.1016\/j.cll.2026.02.006_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12648","article-title":"Direct oral anticoagulants-Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors","volume":"6","author":"White","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.cll.2026.02.006_bib48","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1515\/cclm-2018-0967","article-title":"Effect of an activated charcoal product (DOAC StopTM) intended for extracting DOACs on various other APTT-prolonging anticoagulants","volume":"57","author":"Exner","year":"2019","journal-title":"Clin Chem Lab Med"},{"issue":"14","key":"10.1016\/j.cll.2026.02.006_bib49","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1177\/09612033231211820","article-title":"16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends","volume":"32","author":"Atsumi","year":"2023","journal-title":"Lupus"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2026.02.006_bib50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ijlh.13196","article-title":"The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays","volume":"42","author":"Exner","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"8","key":"10.1016\/j.cll.2026.02.006_bib51","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/jth.14488","article-title":"Resolving DOAC interference on aPTT, PT, and lupus anticoagulant testing by the use of activated carbon","volume":"17","author":"Frans","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib52","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/rth2.12472","article-title":"DOAC-Stop in lupus anticoagulant testing: direct oral anticoagulant interference removed in most samples","volume":"5","author":"Baker","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.cll.2026.02.006_bib53","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619872556","article-title":"Evaluation of the DOAC-Stop procedure by LC-MS\/MS assays for determining the residual activity of dabigatran, rivaroxaban, and apixaban","volume":"25","author":"Slavik","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"10.1016\/j.cll.2026.02.006_bib54","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1055\/s-0042-1744364","article-title":"Solid phase assays for antiphospholipid antibodies","volume":"48","author":"Devreese","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.cll.2026.02.006_bib55","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clim.2019.06.002","article-title":"News and meta-analysis regarding anti-beta 2 glycoprotein I antibodies and their determination","volume":"205","author":"Bettacchioli","year":"2019","journal-title":"Clin Immunol Orlando Fla"},{"issue":"20","key":"10.1016\/j.cll.2026.02.006_bib56","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/bloodadvances.2021005205","article-title":"A systematic review of the association between anti-\u03b2-2 glycoprotein I antibodies and APS manifestations","volume":"5","author":"Jiang","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.cll.2026.02.006_bib57","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/ijlh.12234","article-title":"Antiphospholipid antibody testing and standardization","volume":"36","author":"Devreese","year":"2014","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"10.1016\/j.cll.2026.02.006_bib58","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1055\/s-0032-1304714","article-title":"Interference in antiphospholipid antibody assays","volume":"38","author":"Lakos","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1016\/j.cll.2026.02.006_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/jth.13560","article-title":"A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system","volume":"15","author":"Devreese","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.cll.2026.02.006_bib60","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1055\/s-0039-1679901","article-title":"Detection of anti-cardiolipin and Anti-\u03b22glycoprotein I antibodies differs between platforms without influence on Association with clinical symptoms","volume":"119","author":"Chayoua","year":"2019","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib61","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jth.15585","article-title":"Semiquantitative interpretation of anticardiolipin and anti\u03b22glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"20","author":"Vandevelde","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.cll.2026.02.006_bib62","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jtha.2024.09.021","volume":"23","author":"Meroni","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cll.2026.02.006_bib63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21037\/aob.2019.10.01","article-title":"A review of 10 years of data from an external quality assurance program for antiphospholipid antibodies: no evidence for improved aCL and \u03b22GPI assay standardization","volume":"4","author":"Wienholt","year":"2019","journal-title":"Ann Blood"},{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib64","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1055\/s-0033-1364207","article-title":"Standardization of antiphospholipid antibody testing--historical perspectives and ongoing initiatives","volume":"40","author":"Willis","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib65","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1515\/cclm-2020-0995","article-title":"Development of a certified reference material for anti-\u03b22-glycoprotein I IgG - commutability studies","volume":"59","author":"Monogioudi","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"10.1016\/j.cll.2026.02.006_bib66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/jth.14633","article-title":"The (non-)sense of detecting anti-cardiolipin and anti-\u03b22glycoprotein I IgM antibodies in the antiphospholipid syndrome","volume":"18","author":"Chayoua","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.cll.2026.02.006_bib67","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/keaa203","article-title":"EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies","volume":"60","author":"Pregnolato","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"issue":"8","key":"10.1016\/j.cll.2026.02.006_bib68","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jtha.2024.04.016","volume":"22","author":"Vandevelde","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2026.02.006_bib69","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ijlh.14268","article-title":"Noncriteria antiphospholipid antibodies in antiphospholipid syndrome","volume":"46","author":"Devreese","year":"2024","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib70","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/keab414","article-title":"\u201cNon-criteria antiphospholipid antibodies\u201d: bridging the gap between seropositive and seronegative antiphospholipid syndrome","volume":"61","author":"Truglia","year":"2022","journal-title":"Rheumatol Oxf Engl"},{"issue":"11","key":"10.1016\/j.cll.2026.02.006_bib71","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1055\/s-0040-1714653","article-title":"Is there an additional value in detecting anticardiolipin and Anti-\u03b22 glycoprotein I IgA antibodies in the antiphospholipid syndrome?","volume":"120","author":"Chayoua","year":"2020","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib72","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/jth.14682","article-title":"Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: a multicenter multiplatform study","volume":"18","author":"Yin","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cll.2026.02.006_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.754469","article-title":"Anti-Phosphatidylserine\/Prothrombin antibodies at two points: correlation with lupus anticoagulant and thrombotic risk","volume":"12","author":"Egri","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.cll.2026.02.006_bib74","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/jth.14765","article-title":"Tetra positive thrombotic antiphospholipid syndrome: major contribution of anti-phosphatidyl-serine\/prothrombin antibodies to lupus anticoagulant activity","volume":"18","author":"Cattini","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.cll.2026.02.006_bib75","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jth.14261","article-title":"Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-\u03b22glycoprotein I antibody detection assays","volume":"16","author":"Chayoua","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.cll.2026.02.006_bib76","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0961203316657433","article-title":"Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity","volume":"26","author":"Yelnik","year":"2017","journal-title":"Lupus"},{"issue":"13","key":"10.1016\/j.cll.2026.02.006_bib77","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cll.2026.02.006_bib78","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and haemostasis","volume":"18","author":"Zuily","year":"2020","journal-title":"J Thromb Haemost"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:04:50Z","timestamp":1783620290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271226000065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0272271226000065"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2026.02.006","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in Antiphospholipid Syndrome Laboratory Diagnosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2026.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}